Skip to main content

Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.

Publication ,  Journal Article
Ellingson, BM; Sampson, J; Achrol, AS; Aghi, MK; Bankiewicz, K; Wang, C; Bexon, M; Brem, S; Brenner, A; Chowdhary, S; Floyd, JR; Han, S ...
Published in: Clin Cancer Res
July 15, 2021

PURPOSE: The current study compared the standard response assessment in neuro-oncology (RANO), immunotherapy RANO (iRANO), and modified RANO (mRANO) criteria as well as quantified the association between progression-free (PFS) and overall survival (OS) in an immunotherapy trial in recurrent glioblastoma (rGBM). PATIENTS AND METHODS: A total of 47 patients with rGBM were enrolled in a prospective phase II convection-enhanced delivery of an IL4R-targeted immunotoxin (MDNA55-05, NCT02858895). Bidirectional tumor measurements were created by local sites and centrally by an independent radiologic faculty, then standard RANO, iRANO, and mRANO criteria were applied. RESULTS: A total of 41 of 47 patients (mean age 56 ± 11.7) were evaluable for response. PFS was significantly shorter using standard RANO compared with iRANO (log-rank, P < 0.0001; HR = 0.3) and mRANO (P < 0.0001; HR = 0.3). In patients who died and had confirmed progression on standard RANO, no correlation was observed between PFS and OS (local, P = 0.47; central, P = 0.34). Using iRANO, a weak association was observed between confirmed PFS and OS via local site measurements (P = 0.017), but not central measurements (P = 0.18). A total of 24 of 41 patients (59%) were censored using iRANO and because they lacked confirmation of progression 3 months after initial progression. A strong correlation was observed between mRANO PFS and OS for both local (R2 = 0.66, P < 0.0001) and centrally determined reads (R2 = 0.57, P = 0.0007). CONCLUSIONS: No correlation between radiographic PFS and OS was observed for standard RANO or iRANO, but a correlation was observed between PFS and OS using the mRANO criteria. Also, the iRANO criteria was difficult to implement due to need to confirm progression 3 months after initial progression, censoring more than half the patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

July 15, 2021

Volume

27

Issue

14

Start / End Page

3916 / 3925

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Nervous System Neoplasms
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Interleukin-4 Receptor alpha Subunit
  • Immunotoxins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ellingson, B. M., Sampson, J., Achrol, A. S., Aghi, M. K., Bankiewicz, K., Wang, C., … Merchant, F. (2021). Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clin Cancer Res, 27(14), 3916–3925. https://doi.org/10.1158/1078-0432.CCR-21-0446
Ellingson, Benjamin M., John Sampson, Achal Singh Achrol, Manish K. Aghi, Krystof Bankiewicz, Chencai Wang, Martin Bexon, et al. “Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.Clin Cancer Res 27, no. 14 (July 15, 2021): 3916–25. https://doi.org/10.1158/1078-0432.CCR-21-0446.
Ellingson BM, Sampson J, Achrol AS, Aghi MK, Bankiewicz K, Wang C, et al. Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clin Cancer Res. 2021 Jul 15;27(14):3916–25.
Ellingson, Benjamin M., et al. “Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.Clin Cancer Res, vol. 27, no. 14, July 2021, pp. 3916–25. Pubmed, doi:10.1158/1078-0432.CCR-21-0446.
Ellingson BM, Sampson J, Achrol AS, Aghi MK, Bankiewicz K, Wang C, Bexon M, Brem S, Brenner A, Chowdhary S, Floyd JR, Han S, Kesari S, Randazzo D, Vogelbaum MA, Vrionis F, Zabek M, Butowski N, Coello M, Merchant N, Merchant F. Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clin Cancer Res. 2021 Jul 15;27(14):3916–3925.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

July 15, 2021

Volume

27

Issue

14

Start / End Page

3916 / 3925

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Nervous System Neoplasms
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Interleukin-4 Receptor alpha Subunit
  • Immunotoxins